Nebulized Furosemide in the Treatment of Bronchopulmonary Dysplasia in Preterm Infants

Sahni, Jasmine; Phelps, Stephanie J.

doi:10.5863/1551-6776-16.1.14

Cited by 7 publications

(3 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is important especially when some of the antibiotics required to treat multidrug resistant infections have serious systemic toxicity, but also given the concerns around antibiotic resistance and the need to control the doses of these powerful drugs. 7,106 There are many publications outlining the use of VMNs for delivery of heparin for pulmonary inflammation in ventilated patients, 32 antifungals for invasive aspergillosis, [107][108][109] furosemide for COPD exacerbations, surfactant for neonates, prostacyclins for pulmonary hypertension, bronchopulmonary dysplasia and breathlessness in lung cancer, 33,110,111 and the administration of insulin to patients with diabetes. [112][113][114] However, many of these drugs are not approved for inhalation or are not specifically approved for inhalation with a VMN and are off label.…”

Section: Discussion and Future Directionsmentioning

confidence: 99%

Vibrating Mesh Nebulisers – Can Greater Drug Delivery to the Airways and Lungs Improve Respiratory Outcomes?

Ehrmann¹

2018

European Respiratory &Amp; Pulmonary Diseases

View full text Add to dashboard Cite

Aerosols are an increasingly important mode of delivery of drugs, particularly bronchodilators, for the treatment of respiratory diseases, notably asthma and chronic obstructive pulmonary disease. The most common type of nebuliser is the jet nebuliser (JN); they have been in use for more than a century but these devices can be cumbersome to use and may sometimes deliver insufficient amounts of drug. A more recent development in aerosol therapy is the vibrating mesh nebuliser (VMN) which is very user friendly and is more efficient than the JNs due to an extremely low residual volume. Scintigraphy images from studies of volunteer subjects using radio-labelled aerosol treatment show that VMN-generated aerosols deliver more drug to patients in a shorter period of time than JN-generated aerosols. Various bench, animal model and small clinical studies have shown that VMNs are more efficient than JNs in drug delivery, potentially improving clinical outcomes. These studies have included various breathing circuits used in mechanical ventilation (MV), non-invasive ventilation, high-flow nasal cannula systems and devices for spontaneously breathing patients. The efficiency of drug delivery was affected by factors including the position of the nebuliser in the circuit and humidity. Some studies have shown potential substantial savings by hospitals in the cost of MV treatments after switching from metered dose inhalers to VMNs. VMNs have also been shown to be effective for the administration of inhaled antibiotics, corticosteroids and other drugs. Larger studies of the effects of VMNs on patient outcomes are needed but they are likely to be an increasingly important means of administering therapies to a burgeoning population with respiratory disease.

show abstract

Section: Discussion and Future Directionsmentioning

confidence: 99%

Vibrating Mesh Nebulisers – Can Greater Drug Delivery to the Airways and Lungs Improve Respiratory Outcomes?

Ehrmann¹

2018

European Respiratory &Amp; Pulmonary Diseases

View full text Add to dashboard Cite

show abstract

“…Adverse effects of long-term therapy are recurrent and include hyponatremia, hypokalemia, contraction alkalosis, hypocalcemia, hypercalciuria, renal stones, nephrocalcinosis and ototoxicity. However, long-term benefits have not been established in infants with BPD (9,10,11,12).…”

Section: Diureticsmentioning

confidence: 99%

Bronchopulmonary Dysplasia: Treatment and Prevention

Cerović,

Živković,

Veković

et al. 2016

Prev Ped

View full text Add to dashboard Cite

Since 1967, when it was first defined and described the nature and definition of bronchopulmonary dysplasia (BPD) has evolved. Based on clinical and radiographic evidence of pulmonary disease in moderately to late premature infants with a history of respiratory distress syndrome, BPD was familiarly defined as a chronic form of lung disease in neonates treated with oxygen and positive pressure ventilation for a primary lung disorder, the nature of BPD has evolved into a “new” form of BPD typically seen in neonates surviving at the threshold of viability and characterized primarily by arrest of alveolar and vascular development. Infants develop BPD in about 1.5% of all newborn births. The incidence of BPD appears to be growing in conjunction with the increased survival of very-low-birth-weight infants who are treated for and recover from respiratory distress syndrome (RDS). This review has been an up-date of literature data, including animal studies, human pilot studies, randomized controlled trials (RCTs), meta-analyses and systematic reviews published on the PubMed data base.

show abstract

“…Bronchopulmonary dysplasia (BPD) is the most common and serious complication in preterm babies, with rates reaching up to 45% in infants born at < 29 weeks gestational age (Eduardo et al 2017 ; Sahni and Phelps 2011 ). The mortality and complication rates of preterm infants with BPD are significantly higher than those of preterm infants without BPD.…”

Section: Introductionmentioning

confidence: 99%

Rad1 attenuates DNA double-strand breaks and cell cycle arrest in type II alveolar epithelial cells of rats with bronchopulmonary dysplasia

Tong

Liu

et al. 2023

Mol Med

View full text Add to dashboard Cite

Background Bronchopulmonary dysplasia (BPD) is the most common and serious chronic lung disease in preterm infants with pathological characteristics of arrested lung development. DNA double-strand breaks (DSBs) are a serious manifestation of oxidative stress damage, but little is known about the role of DSBs in BPD. The current study set out to detect DSB accumulation and cell cycle arrest in BPD and study the expression of genes related to DNA damage and repair in BPD through DNA damage signaling pathway-based PCR array to determine a suitable target to improve arrested lung development associated with BPD. Methods DSB accumulation and cell cycle arrest were detected in a BPD animal model and primary cells, then a DNA damage signaling pathway-based PCR array was used to identify the target of DSB repair in BPD. Results DSB accumulation and cell cycle arrest were shown in BPD animal model, primary type II alveolar epithelial cells (AECII) and cultured cells after exposure to hyperoxia. Of the 84 genes in the DNA damage-signaling pathway PCR array, eight genes were overexpressed and 11 genes were repressed. Rad1, an important protein for DSB repair, was repressed in the model group. Real-time PCR and western blots were used to verify the microarray results. Next, we confirmed that silencing Rad1 expression aggravated the accumulation of DSBs and cell cycle arrest in AECII cells, whereas its overexpression alleviated DSB accumulation and cell cycle arrest. Conclusions The accumulation of DSBs in AECII might be an important cause of alveolar growth arrest associated with BPD. Rad1 could be an effective target for intervention to improve this arrest in lung development associated with BPD.

show abstract

Nebulized Furosemide in the Treatment of Bronchopulmonary Dysplasia in Preterm Infants

Cited by 7 publications

References 44 publications

Vibrating Mesh Nebulisers – Can Greater Drug Delivery to the Airways and Lungs Improve Respiratory Outcomes?

Vibrating Mesh Nebulisers – Can Greater Drug Delivery to the Airways and Lungs Improve Respiratory Outcomes?

Bronchopulmonary Dysplasia: Treatment and Prevention

Rad1 attenuates DNA double-strand breaks and cell cycle arrest in type II alveolar epithelial cells of rats with bronchopulmonary dysplasia

Contact Info

Product

Resources

About